Polysialic EPO : ErepoXen®
ErepoXen® is a new product candidate from Lipoxen which potentially offers an improved form of erythropoietin (EPO). EPO is a hormone produced by the kidneys to maintain red blood cell production and prevent anaemia. Chronic renal (kidney) failure or chemotherapy to treat cancer can cause anaemia. In cases of renal failure, the kidneys no longer manufacture enough of the erythropoietin hormone and this causes anaemia. EPO therapy is the treatment for this anaemia.
ErepoXen® offers benefits such as:
- Reducing the frequency of dosage required
- Reducing immunogenicity
- Reducing toxicity
How could ErepoXen® improve the performance of erythropoietin (EPO)?
ErepoXen® is a performance-enhanced polysialylated form of EPO. It was developed to reduce the required frequency of dosage and to be less immunogenic.
A further potential benefit of ErepoXen® is that it uses polysialic acid (PSA). PSA is a polymer of sialic acid (a sugar) and it is found naturally in the human body. Most importantly, PSA is biodegradable.